Emerging gene editing platforms are revolutionizing precision medicine, enabling safe and effective genetic modifications for ...

Intellia Therapeutics, Inc. NTLA stock is trading higher on Monday on additional positive findings from its global Phase 3 ...

The company seems to be doing everything it's supposed to be doing; the stock just isn't responding.

It's a "gateway to embryo editing to do enhancements." The post Scientists Concerned Latest Gene Editing of Human Embryos ...

Are there significant gains ahead for one (or both) of these innovative biotechs?

Researchers relied on a newer gene-editing technique that may make it possible to engineer embryos, a prospect that has long ...

CRISPR Therapeutics (NasdaqGM:CRSP) filed a large shelf registration, creating capacity to issue new securities over time.

A team in the US has reported promising results after using an improved form of CRISPR to gene-edit human embryos, but a ...

Crispr Therapeutics (CRSP) is downgraded to "Hold" as current valuation already reflects optimism for CTX310 Phase I results and pipeline progress. Intellia Therapeutics (NTLA) maintains a "Buy" ...

A team of researchers led by Luigi Naldini at the San Raffael Institute for Gene Therapy (SR-Tiget) has developed a new ...

Phase III trial shows majority of patients become attack-free without ongoing meds ...

A major medical milestone took place in May 2025, when doctors at the Children’s Hospital of Philadelphia used CRISPR-based gene editing to treat a child with a rare genetic disorder. Unlike earlier ...